Replimune Ltd. named Hyam Levitsky to the board as a nonexecutive director.
Previously, Levitsky served as executive vice president of research and chief scientific officer at Juno Therapeutics Inc., which was recently acquired by Celgene Corp.
Woburn, Mass.-based Replimune Group is a biotechnology company developing oncolytic immunotherapies.
